64 results about "Thioredoxin reductase" patented technology

The present invention provides novel emulsion formulations which comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in a variety of products including food products, personal care products and pharmaceutical products. In a preferred embodiment the emulsions comprise thioredoxin and/or thioredoxin reductase.

The invention discloses a novel antitumor medicament, in particular a benzisoselenazolone difluorocytidine compound or a pharmaceutically acceptable salt or ester thereof as well as a preparation method and application thereof, wherein a benzisoselenazolone structure can identify selenocysteine residues in the activity center of thioredoxin reductase to generate the action of reversibly competitive inhibition and reserves the activity structure of 2'-deoxidization-2'2'-difluorocytidine. Therefore, the benzisoselenazolone difluorocytidine compound in the invention can selectively kill tumor cells, inhibit the growth of the tumor cells, and has the characteristics of high efficiency and low toxicity.

Provided herein is a method of treating cancer by the administration of binuclear gold(I) compounds in patients in need thereof. The pharmaceutical compounds possess anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase activity, and inhibition of tumor growth in vivo.

The present invention relates to a method for investigating body fluids for cancer cells, the use thereof and corresponding analysis kits, and the possibilities for cancer treatment derived therefrom. The method is based essentially on determining the expression of the manganese superoxide dismutase, thioredoxin reductase and/or glutathione peroxidase genes. Use of this method permits in particular reliable tumor diagnosis and prognosis. Diminishing an elevated expression of these genes has therapeutic value and may be utilized for cancer treatment.

The mechanism of action of Ebselen differentiates between bacterial and mammalian thioredoxin reductase (TrxR). It displays fast oxidation of mammalian Trx and via the NADPH-TrxR catalyzed turnover of ebselen selenol with hydrogen peroxide, and therefore are mammalian antioxidants. Ebselen, and its diselenide, are strong competitive inhibitors of E. coli TrxR with K_i of 0.14 μM and 0.46 μM, respectively. E. coli mutants lacking glutathione reductase or glutathione were much more sensitive to inhibition by ebselen. Since either glutaredoxin or thioredoxin systems are electron donors to ribonucleotide reductase, ebselen targets primarily glutathione and glutaredoxin-negative bacteria, a class which includes major pathogens. Ebselen, and similar compounds are therefore useful as antibacterial agents, even for multiresistant strains. Two major pathogenic bacteria, which previously had not been known to be sensitive to ebselen, Mycobacterium tuberculosis (tuberculosis) and Helicobacter pylori (stomach ulcer and cancer), were shown to be excellent targets. Helicobacter pylori was also sensitive to ebsulfur.

The invention discloses an organoarsenic compound. The organoarsenic compound has the following structural formula as shown in the specification, wherein n is 1 or 2; R, R1, R2, R3, R4 and R5 are respectively and independently amino, R6-CO-NH, R7-CO-O, alkyl, aryl, a heterocyclic substituent, alkoxyl, alkylamino, a halogen atom, nitro, hydroxyl or a hydrogen atom; R6 is alkyl, aminoalkyl or aryl;R7 is alkyl, aminoaryl or aryl. The organoarsenic compound has good inhibitory activity for thioredoxin reductase, has strong cytotoxicity for tumor cell HL-60, and can be used for preparing a thioredoxin reductase inhibitor or an antitumor drug with thioredoxin reductase as a target spot.

Antisense oligomers directed to bacterial cell division and cell cycle-encoding nucleic acids are capable of selectively modulating the biological activity thereof, and are useful in treatment and prevention of bacterial infection. The antisense oligomers are substantially uncharged, and contain from 8 to 40 nucleotide subunits, including a targeting nucleic acid sequence at least 10 nucleotides in length which is effective to hybridize to (i) a bacterial tRNA or (ii) a target sequence, containing a translational start codon, within a bacterial nucleic acid which encodes a protein associated with cell division or the cell cycle. Such proteins include zipA, sulA, secA, dicA, dicB, diCc, dicF, ftsA, ftsl,ftsN, ftsK, ftsL, ftsQ, ftsw, ftsZ, murC, murD, murE, murF, murg, minC, minD, minE, mraY, mraW, mraZ, seqA, ddlB, carbamate kinase, D-ala D-ala ligase, topoisomerase, alkyl hydroperoxide reductase, thioredoxin reductase, dihydrofolate reductase, and cell wall enzyme.

Activation of HIV-1 replication causes oxidative stress, which in turn potentiates HIV-1 replication. The common basis for the compounds of the present invention is: A) the capacity of reactivating HIV-1 from latency, and B) the ability to counteract the cellular machinery which activates in order to limit the effects of oxidative stress. In this way, oxidative stress can be potentiated and a “chain reaction” is sparked. This “chain reaction” induces a more efficient reactivation of HIV-1 from latency and, in some cases, induces selective killing of the infected cells. Actions A) and B) can either be carried out by one drug exerting both effects, or obtained by the combined use of distinct drugs. There are two main cellular machineries counteracting oxidative stress, i.e. the thioredoxin (Trx) thioredoxin reductase (TrxR) system and glutathione. Herein, we present drug strategies capable of exerting action B) by blocking either of the two machineries.

The invention belongs to the field of immunodiagnosis and discloses an aspergillus immunodominance antigen and an application thereof. The antigen is one or more of aspergillus thioredoxin reductase, fructose-bisphosphate aldolase, actin cytoskeleton protein V1P1 and secretory dipeptidyl peptidase. The aspergillus immunodominance antigen can react with specific antibodies in the serums of the patients suffering from invasive aspergillosis strongly and can be used for preparing a diagnostic reagent of invasive aspergillosis.

The invention discloses a synergistic detection device for thioredoxin reductase activity. The synergistic detection device comprises a detection machine, a detection cavity is arranged in the detection machine, a detection mechanism supporting experiments is arranged in the detection cavity, a driving mechanism is arranged in the lower end wall of the detection cavity to provide power for the operation of he device and includes a driving cavity, a motor is arranged on in the lower end wall of the driving cavity, a cleaning mechanism capable of cleaning and drying carriers is further arranged in the detection machine, and an adding mechanism for adding required reagents or detection samples to the carriers is further arranged in the upper end wall of the detection cavity. The device can automatically complete the addition of the samples or reagents when detection is needed, manual addition is not needed, the interference of other factors to the detection is reduced, the accuracy of the detection is improved, a culture dish is cleaned and dried at the beginning and end of the detection to ensure the cleanliness of the culture dish and less influence on the detection, and through mechanical transmission, the efficiency of the detection is improved.

The invention relates to an enzyme extraction and purification technology, specifically to a method of extracting and purifying thioredoxin reductase from chicken livers. The method comprises steps of obtaining a crude extract from fresh chicken livers; salting out; and extracting and purifying thioredoxin reductase from chicken livers by employing chromatography that uses two chromatography media comprising a DEAE anion exchange chromatography column and an ADP affinity chromatography column. The method provided by the invention is advantageous in that the raw material chicken livers have wide source and low cost; process of the extraction and purification technology is simple, and can be operated conveniently; finished products have high purity and the same capability of catalyzing human Trx reduction as cattle or mouse thioredoxin reductase, and therefore the finished products can be applied to scientific researches and practices, in place of cattle or mouse thioredoxin reductase, for human-related disease researches; and problems, of extraction and purification processes for cattle or mouse TrxR, comprising difficulty in obtaining raw materials, large individual differences, etc. are solved. The method provided by the invention fills in the blank of biological reagent preparations in our country and has high economic value.

The invention provides a method for preparing fusion protein capable of lowering food allergen reaction, comprising the following steps: obtaining a thioredoxin gene Trx and a thioredoxin reductase gene TrxR in a thioredoxin system; designing a fusion peptide sequence; fusing the genes Trx and TrxR by the fusion peptide sequence; then, obtaining a recombination strain containing the fusion gene; and finally, carrying out heterology expression purification. The invention colons the genes of two proteins in an AnTrx system with wide application meaning in the industry and fuses and improves thegenes of Trx and TrxR, and a disulfide bond in the food protein is reduced by incubating with the food protein so as to lower the allergen reaction thereof. Meanwhile, improvement by gene fusion causes An-TrxR and An-Trx to be convenient to apply in the food industry when An-TrxR and An-Trx serve as a food additive.

The invention discloses a golden phosphorous acetyletic compound in the general formula, and a preparation method and applications thereof. The golden phosphorous acetyletic compound has stronger in-vivo stability, and can efficiently and specifically inhibit the activity of thioredoxin reductase in a targeted manner, thus inhibiting the increase of tumor through damaging intracellular redox level; in addition, better in-vitro and in-vivo tumor inhibition effects can be achieved, the targeted tumor treatment effect can be realized, and the golden phosphorous acetyletic compound has wide application prospects.

The invention belongs to the technical field of biomedicine and relates to kluyveromyces marxianus-derived alkyl peroxide reductase and thioredoxin reductase and an application thereof in improving stress resistance. The KmTPX1 gene of alkyl peroxide reductase gene contains 594 nucleotides, and 197 amino acids are coded; and the KmTrxR gene contains 960 nucleotides, and 319 amino acids are coded. Meanwhile, the KmTPX1 gene and KmTrxR gene can improve the tolerance of yeast cells against multiple inhibitors or stress factors, such as one or more of hydrogen peroxide, formic acid, acetic acid, furfural, ethanol, sodium chloride, phenol and guaiacol. Due to the improvement of the tolerance against formic acid, acetic acid, furfural, ethanol and salt ion concentration, the alkyl peroxide reductase gene and thioredoxin reductase gene play a crucial role in constructing a good cellulosic ethanol fermentation strain.